Adam is an Executive Director and External Accelerator Lead at Pfizer where he creates proactive partnerships and business development deals to build value for Pfizer’s portfolio. He has more than 29 years of experience working in biopharma and recently led Pfizer’s Design and Synthesis Sciences platform medicinal chemistry group which successfully delivered targeted covalent inhibitors, protein homeostasis modulators, and vaccine antigens to Pfizer’s clinical portfolio. He is a co-inventor of LITFULO™ (Ritlecitinib), a covalent JAK3/TEC inhibitor that was recently approved to treat Alopecia Areata and his group helped deliver ABRYSVO™ (RSVPreF), a preventative Respiratory Syncytial Virus vaccine and COMIRNATY® (BNT162b2) an mRNA COVID-19 vaccine. Adam received a Ph.D. in Organic Chemistry from Columbia University.